Cargando…

Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases

BACKGROUND: Clinical exome sequencing (CES) provides a comprehensive and effective analysis of relevant disease-associated genes in a cost-effective manner compared to whole exome sequencing. Although several studies have focused on the diagnostic yield of CES, no study has assessed predictors of CE...

Descripción completa

Detalles Bibliográficos
Autores principales: Alix, Tom, Chéry, Céline, Josse, Thomas, Bronowicki, Jean-Pierre, Feillet, François, Guéant-Rodriguez, Rosa-Maria, Namour, Farès, Guéant, Jean-Louis, Oussalah, Abderrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899384/
https://www.ncbi.nlm.nih.gov/pubmed/36740706
http://dx.doi.org/10.1186/s40246-023-00455-x
_version_ 1784882625669758976
author Alix, Tom
Chéry, Céline
Josse, Thomas
Bronowicki, Jean-Pierre
Feillet, François
Guéant-Rodriguez, Rosa-Maria
Namour, Farès
Guéant, Jean-Louis
Oussalah, Abderrahim
author_facet Alix, Tom
Chéry, Céline
Josse, Thomas
Bronowicki, Jean-Pierre
Feillet, François
Guéant-Rodriguez, Rosa-Maria
Namour, Farès
Guéant, Jean-Louis
Oussalah, Abderrahim
author_sort Alix, Tom
collection PubMed
description BACKGROUND: Clinical exome sequencing (CES) provides a comprehensive and effective analysis of relevant disease-associated genes in a cost-effective manner compared to whole exome sequencing. Although several studies have focused on the diagnostic yield of CES, no study has assessed predictors of CES utility among patients with various Mendelian phenotypes. We assessed the effectiveness of CES as a first-level genetic test for molecular diagnosis in patients with a Mendelian phenotype and explored independent predictors of the clinical utility of CES. RESULTS: Between January 2016 and December 2019, 603 patients (426 probands and 177 siblings) underwent CES at the Department of Molecular Medicine of the University Hospital of Nancy. The median age of the probands was 34 years (IQR, 12–48), and the proportion of males was 46.9% (200/426). Adults and children represented 64.8% (276/426) and 35.2% (150/426), respectively. The median test-to-report time was 5.6 months (IQR, 4.1–7.2). CES revealed 203 pathogenic or likely pathogenic variants in 160 patients, corresponding to a diagnostic yield of 37.6% (160/426). Independent predictors of CES utility were criteria strongly suggestive of an extreme phenotype, including pediatric presentation and patient phenotypes associated with an increased risk of a priori probability of a monogenic disorder, the inclusion of at least one family member in addition to the proband, and a CES prescription performed by an expert in the field of rare genetic disorders. CONCLUSIONS: Based on a large dataset of consecutive patients with various Mendelian phenotypes referred for CES as a first-tier genetic test, we report a diagnostic yield of ~ 40% and several independent predictors of CES utility that might improve CES diagnostic efficiency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40246-023-00455-x.
format Online
Article
Text
id pubmed-9899384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98993842023-02-06 Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases Alix, Tom Chéry, Céline Josse, Thomas Bronowicki, Jean-Pierre Feillet, François Guéant-Rodriguez, Rosa-Maria Namour, Farès Guéant, Jean-Louis Oussalah, Abderrahim Hum Genomics Research BACKGROUND: Clinical exome sequencing (CES) provides a comprehensive and effective analysis of relevant disease-associated genes in a cost-effective manner compared to whole exome sequencing. Although several studies have focused on the diagnostic yield of CES, no study has assessed predictors of CES utility among patients with various Mendelian phenotypes. We assessed the effectiveness of CES as a first-level genetic test for molecular diagnosis in patients with a Mendelian phenotype and explored independent predictors of the clinical utility of CES. RESULTS: Between January 2016 and December 2019, 603 patients (426 probands and 177 siblings) underwent CES at the Department of Molecular Medicine of the University Hospital of Nancy. The median age of the probands was 34 years (IQR, 12–48), and the proportion of males was 46.9% (200/426). Adults and children represented 64.8% (276/426) and 35.2% (150/426), respectively. The median test-to-report time was 5.6 months (IQR, 4.1–7.2). CES revealed 203 pathogenic or likely pathogenic variants in 160 patients, corresponding to a diagnostic yield of 37.6% (160/426). Independent predictors of CES utility were criteria strongly suggestive of an extreme phenotype, including pediatric presentation and patient phenotypes associated with an increased risk of a priori probability of a monogenic disorder, the inclusion of at least one family member in addition to the proband, and a CES prescription performed by an expert in the field of rare genetic disorders. CONCLUSIONS: Based on a large dataset of consecutive patients with various Mendelian phenotypes referred for CES as a first-tier genetic test, we report a diagnostic yield of ~ 40% and several independent predictors of CES utility that might improve CES diagnostic efficiency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40246-023-00455-x. BioMed Central 2023-02-05 /pmc/articles/PMC9899384/ /pubmed/36740706 http://dx.doi.org/10.1186/s40246-023-00455-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Alix, Tom
Chéry, Céline
Josse, Thomas
Bronowicki, Jean-Pierre
Feillet, François
Guéant-Rodriguez, Rosa-Maria
Namour, Farès
Guéant, Jean-Louis
Oussalah, Abderrahim
Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases
title Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases
title_full Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases
title_fullStr Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases
title_full_unstemmed Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases
title_short Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases
title_sort predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with mendelian phenotypes: results from a referral center study on 603 consecutive cases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899384/
https://www.ncbi.nlm.nih.gov/pubmed/36740706
http://dx.doi.org/10.1186/s40246-023-00455-x
work_keys_str_mv AT alixtom predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT cheryceline predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT jossethomas predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT bronowickijeanpierre predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT feilletfrancois predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT gueantrodriguezrosamaria predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT namourfares predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT gueantjeanlouis predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases
AT oussalahabderrahim predictorsoftheutilityofclinicalexomesequencingasafirsttiergenetictestinpatientswithmendelianphenotypesresultsfromareferralcenterstudyon603consecutivecases